NHS criticised for lax control over drugs industry

BMJ 2005; 330 doi: 10.1136/bmj.330.7495.805 (Published 7 April 2005)
Cite this as: BMJ 2005;330:805.1

This article has a correction

Please see: Two drug firms advertised to patients

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Zosia Kmietowicz
  1. London

    Links between the pharmaceutical industry and the UK Department of Health have become so intertwined that the public's health is being put at risk, says a highly critical report from a cross party group of MPs, published this week. The much anticipated report cites multiple failings at the United Kingdom's drug regulatory body for not scrutinising thoroughly enough data from companies seeking licences for new drugs and for not monitoring side effects adequately.

    It also blames lax controls at the Department of Health for allowing pharmaceutical companies to have expanded influence over the public and the medical profession, which has led to overprescribing by doctors and an unhealthy reliance on medicines by the public.

    The report, from the House of Commons health select committee, recommends a …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL